Literature DB >> 1365674

Specific effects of the benzodiazepine midazolam on visual receptive fields in light and dark adapted human subjects.

M Groner1, H U Fisch, F Walder, R Groner, D Hofer, U Koelbing, I Duss, R Bianchi, B Bircher.   

Abstract

Psychophysical experiments in humans have revealed similar characteristics of visual receptive fields as were found in cats and monkeys from retinal ganglion cell recordings. In addition, in some retinal ganglion cells of cats the GABA antagonist bicuculline decreases the activity of the inhibitory surround. These findings led to two predicitions: 1) benzodiazepines will selectively increase the inhibitory surround of human visual receptive fields, 2) after dark adaptation, no free GABA will be available in the synapses and benzodiazepines will have no effect on the visual system. Characteristics of human receptive fields were determined by subthreshold summation: the contrast threshold of a vertical line was measured dependent on the distance of two parallel flanking lines whose contrast was below threshold. Both hypotheses were confirmed: the threshold in the inhibitory region of receptive fields was specifically increased in a dose-dependent manner by midazolam PO (7.5 mg: P < 0.05; 15 mg: P < 0.01). In dark-adapted subjects no effect of midazolam was found. Control experiments with atropine (1 mg IV), sulpiride (100 mg IM), and levodopa (100 mg PO) showed no specific effect. The visual system may be a model to bridge the gap between animal and human psychopharmacology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365674     DOI: 10.1007/bf02245482

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  The influence of dopamine on spatial vision.

Authors:  J P Harris; J E Calvert; J A Leendertz; O T Phillipson
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

2.  Effects of dopamine and its agonists and antagonists on the receptive field properties of ganglion cells in the rabbit retina.

Authors:  R J Jensen; N W Daw
Journal:  Neuroscience       Date:  1986-03       Impact factor: 3.590

3.  Synaptosomal neurotransmitter uptake systems in the retina and brain nuclei of light- and dark-adapted rabbits.

Authors:  T Chentanez; D A Redburn
Journal:  Brain Res       Date:  1987-10-20       Impact factor: 3.252

4.  Maximum likelihood estimation: the best PEST.

Authors:  A Pentland
Journal:  Percept Psychophys       Date:  1980-10

5.  The shift-effect in retinal ganglion cells of the rhesus monkey.

Authors:  J Krüger; B Fischer; R Barth
Journal:  Exp Brain Res       Date:  1975-10-24       Impact factor: 1.972

6.  Effect of synaptic transmitter drugs on receptive fields of rabbit retinal ganglion cells.

Authors:  N W Daw; M Ariel
Journal:  Vision Res       Date:  1981       Impact factor: 1.886

7.  Dopaminergic drugs improve human visual contrast sensitivity.

Authors:  L Domenici; C Trimarchi; M Piccolino; A Fiorentini; L Maffei
Journal:  Hum Neurobiol       Date:  1985

8.  GABA-antagonists and spatial summation in Y-type cat retinal ganglion cells.

Authors:  A W Kirby; D E Schweitzer-Tong
Journal:  J Physiol       Date:  1981-03       Impact factor: 5.182

Review 9.  Relationship of GABAa receptor heterogeneity to regional differences in drug response.

Authors:  D W Gallager; J F Tallman
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

10.  A tonic gamma-aminobutyric acid-mediated inhibition of cholinergic amacrine cells in rabbit retina.

Authors:  S C Massey; D A Redburn
Journal:  J Neurosci       Date:  1982-11       Impact factor: 6.167

View more
  2 in total

1.  Impairment of contrast sensitivity in long-term lorazepam users.

Authors:  Anne Giersch; Claude Speeg-Schatz; Monique Tondre; Sylvaine Gottenkiene
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

2.  Epilepsy and medication effects on the pattern visual evoked potential.

Authors:  Andrew M Geller; H Ken Hudnell; Bradley V Vaughn; John A Messenheimer; William K Boyes
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.